Skip to main content

Research Repository

Advanced Search

All Outputs (23)

Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival (2020)
Journal Article
Joseph, C., Alsaleem, M., Orah, N., Narasimha, P. L., Miligy, I. M., Kurozumi, S., …Rakha, E. A. (2020). Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival. Breast Cancer Research and Treatment, 182, 267–282. https://doi.org/10.1007/s10549-020-05670-x

Purpose: MMP9 is a matricellular protein associated with extracellular matrix (ECM) remodelling, that promotes tumour progression, and modulates the activity of cell adhesion molecules and cytokines. This study aims to assess the prognostic value of... Read More about Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival.

Metadherin: A Therapeutic Target in Multiple Cancers (2019)
Journal Article
Dhiman, G., Srivastava, N., Goyal, M., Rakha, E., Lothion-Roy, J., Mongan, N. P., …Baranwal, M. (2019). Metadherin: A Therapeutic Target in Multiple Cancers. Frontiers in Oncology, 9, Article 349. https://doi.org/10.3389/fonc.2019.00349

Altered expression of many genes and proteins is essential for cancer development and progression. Recently, the affected expression of metadherin (MTDH), also known as AEG-1 (Astrocyte Elevated Gene 1) and Lyric, has been implicated in various aspec... Read More about Metadherin: A Therapeutic Target in Multiple Cancers.

Targeting PARP1 in XRCC1-deficient sporadic invasive breast cancer or preinvasive ductal carcinoma in situ induces synthetic lethality and chemoprevention (2018)
Journal Article
Ali, R., Al-Kawaz, A., Toss, M. S., Green, A. R., Miligy, I. M., Mesquita, K. A., …Madhusudan, S. (2018). Targeting PARP1 in XRCC1-deficient sporadic invasive breast cancer or preinvasive ductal carcinoma in situ induces synthetic lethality and chemoprevention. Cancer Research, 78(24), 6818-6827. https://doi.org/10.1158/0008-5472.CAN-18-0633

© 2018 American Association for Cancer Research. Targeting PARP1 for synthetic lethality is a new strategy for breast cancers harboring germline mutations in BRCA. However, these mutations are rare, and reactivation of BRCA-mediated pathways may resu... Read More about Targeting PARP1 in XRCC1-deficient sporadic invasive breast cancer or preinvasive ductal carcinoma in situ induces synthetic lethality and chemoprevention.

The spectrum of triple-negative breast disease: high- and low-grade lesions (2018)
Journal Article
Geyer, F. C., Pareja, F., Weigelt, B., Rakha, E., Ellis, I. O., Schnitt, S. J., & Reis-Filho, J. S. (2018). The spectrum of triple-negative breast disease: high- and low-grade lesions. American Journal of Pathology, 187(10), 2139-2151. https://doi.org/10.1016/j.ajpath.2017.03.016

Triple-negative breast cancer is viewed clinically as an aggressive subgroup of breast cancer. In fact, most triple-negative breast cancers are poor-prognosis tumors with a complex genomic landscape. However, triple-negative disease is vastly heterog... Read More about The spectrum of triple-negative breast disease: high- and low-grade lesions.

Breast cancer intratumour heterogeneity: current status and clinical implications (2018)
Journal Article
Joseph, C., Papadaki, A., Althobiti, M., Alsaleem, M., Aleskandarany, M. A., & Rakha, E. A. (2018). Breast cancer intratumour heterogeneity: current status and clinical implications. Histopathology, 73(5), (717-731). doi:10.1111/his.13642. ISSN 0309-0167

Breast cancer (BC) is a heterogeneous disease that varies in presentation, morphological features, behaviour, and response to therapy. High?throughput molecular profiling studies have revolutionised our understanding of BC heterogeneity, and have dem... Read More about Breast cancer intratumour heterogeneity: current status and clinical implications.

Atypical ductal hyperplasia: update on diagnosis, management, and molecular landscape (2018)
Journal Article
Kader, T., Hill, P., Rakha, E. A., Campbell, I. G., & Gorringe, K. L. (2018). Atypical ductal hyperplasia: update on diagnosis, management, and molecular landscape. Breast Cancer Research, 20, 1-11. https://doi.org/10.1186/s13058-018-0967-1

Background Atypical ductal hyperplasia (ADH) is a common diagnosis in the mammographic era and a significant clinical problem with wide variation in diagnosis and treatment. After a diagnosis of ADH on biopsy a proportion are upgraded to carcinoma u... Read More about Atypical ductal hyperplasia: update on diagnosis, management, and molecular landscape.

Tumour heterogeneity of breast cancer: from morphology to personalised medicine (2018)
Journal Article
Aleskandarany, M. A., Vandenberghe, M. E., Marchiò, C., Ellis, I. O., Sapino, A., & Rakha, E. A. (2018). Tumour heterogeneity of breast cancer: from morphology to personalised medicine. Pathobiology, 85(1-2), 23-34. https://doi.org/10.1159/000477851

Breast cancer (BC) displays striking clinical, morphological, and behavioural diversity within a single tumour and between tumours. Currently, mounting evidence indicates that the morphological heterogeneity of BC reflects an underlying spectrum of g... Read More about Tumour heterogeneity of breast cancer: from morphology to personalised medicine.

Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast (2018)
Journal Article
Toss, M. S., Miligy, I., Al-Kawaz, A., Alsleem, M., Khout, H., Rida, P. C., …Rakha, E. (in press). Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast. Modern Pathology, https://doi.org/10.1038/s41379-018-0040-8

Tumor-infiltrating lymphocytes (TILs) provide prognostic value in invasive breast cancer and guidelines for their assessment have been published. This study aims to evaluate: (a) methods of TILs assessment, and (b) their prognostic significance in br... Read More about Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast.

Loss of the nuclear pool of ubiquitin ligase CHIP/STUB1 in breast cancer unleashes the MZF1-cathepsin pro-oncogenic program (2018)
Journal Article
Luan, H., Mohapatra, B. C., Bielecki, T. A., Mushtaq, I., Mirza, S., Jennings, T. A., …Band, H. (2018). Loss of the nuclear pool of ubiquitin ligase CHIP/STUB1 in breast cancer unleashes the MZF1-cathepsin pro-oncogenic program. Cancer Research, 78(10), 2524-2535. https://doi.org/10.1158/0008-5472.CAN-16-2140

CHIP/STUB1 ubiquitin ligase is a negative co-chaperone for HSP90/HSC70, and its expression is reduced or lost in several cancers, including breast cancer. Using an extensive and well-annotated breast cancer tissue collection, we identified the loss o... Read More about Loss of the nuclear pool of ubiquitin ligase CHIP/STUB1 in breast cancer unleashes the MZF1-cathepsin pro-oncogenic program.

First international TNBC conference meeting report (2018)
Journal Article
Rida, P., Ogden, A., Ellis, I. O., Varga, Z., Wolff, A. C., Traina, T. A., …Aneja, R. (2018). First international TNBC conference meeting report. Breast Cancer Research and Treatment, 169(3), 407-412. https://doi.org/10.1007/s10549-018-4692-3

Recently, Georgia State University’s Centennial Hall was the premier location for the 2017 International Conference on Triple Negative Breast Cancer (TNBC): Illuminating Actionable Biology, which was held from Sept. 18 to 20, 2017, in Atlanta, USA. T... Read More about First international TNBC conference meeting report.

IL-6 and IL-10 are associated with good prognosis in early stage invasive breast cancer patients (2017)
Journal Article
Ahmad, N., Ammar, A., Storr, S. J., Green, A. R., Rakha, E., Ellis, I., & Martin, S. G. (2018). IL-6 and IL-10 are associated with good prognosis in early stage invasive breast cancer patients. Cancer Immunology, Immunotherapy, 67(4), https://doi.org/10.1007/s00262-017-2106-8

Macrophage-associated cytokines play an important role in cancer metastasis however the functions of Interleukins (IL) 6 and 10 in breast cancer (BC) progression and metastasis are not clear. In this study the roles of IL-6/IL-10 in regulating vascul... Read More about IL-6 and IL-10 are associated with good prognosis in early stage invasive breast cancer patients.

Invasion in breast lesions: the role of the epithelial-stroma barrier (2017)
Journal Article
Rakha, E. A., Miligy, I., Gorringe, K. L., Toss, M. S., Green, A. R., Fox, S. B., …Ellis, I. O. (2018). Invasion in breast lesions: the role of the epithelial-stroma barrier. Histopathology, 72(7), 1075-1083. https://doi.org/10.1111/his.13446

Despite the significant biological, behavioural and management differences between ductal carcinoma in situ (DCIS) and invasive carcinoma of the breast, they share many morphological and molecular similarities. Differentiation of these two different... Read More about Invasion in breast lesions: the role of the epithelial-stroma barrier.

Diagnostic challenges in papillary lesions of the breast (2017)
Journal Article
Rakha, E. A., & Ellis, I. O. (2017). Diagnostic challenges in papillary lesions of the breast. Pathology, 50(1), (100-110). doi:10.1016/j.pathol.2017.10.005. ISSN 0031-3025

Papillary lesions of the breast comprise a heterogeneous group of diseases ranging from benign and atypical lesions to malignant tumours including non-invasive and invasive entities. Although diagnosis of papillary lesions featuring typical histologi... Read More about Diagnostic challenges in papillary lesions of the breast.

Immunoprofile of metaplastic carcinomas of the breast (2017)
Journal Article
Rakha, E. A., Coimbra, N. D., Hodi, Z., Juneinah, E., Ellis, I. O., & Lee, A. H. (2017). Immunoprofile of metaplastic carcinomas of the breast. Histopathology, 70(6), (975-985). doi:10.1111/his.13159. ISSN 0309-0167

Aims Metaplastic breast carcinoma (MBC) is a rare type of breast cancer; its diagnosis in routine practice can be challenging, and may require immunohistochemical (IHC) characterization if no conventional invasive or in‐situ carcinoma is present. Pr... Read More about Immunoprofile of metaplastic carcinomas of the breast.

Caspase-3 and caspase-8 expression in breast cancer: caspase-3 is associated with survival (2016)
Journal Article
Xuan, P., Storr, S. J., Zhang, Y., Rakha, E., Green, A. R., Ellis, I. O., & Martin, S. G. (in press). Caspase-3 and caspase-8 expression in breast cancer: caspase-3 is associated with survival. Apoptosis, https://doi.org/10.1007/s10495-016-1323-5

Impaired apoptosis is one of the hallmarks of cancer. Caspase-3 and -8 are key regulators of the apoptotic response and have been shown to interact with the calpain family, a group of cysteine proteases, during tumorigenesis. The current study sought... Read More about Caspase-3 and caspase-8 expression in breast cancer: caspase-3 is associated with survival.

Clinicopathological and prognostic significance of mitogen-activated protein kinases (MAPK) in breast cancers (2016)
Journal Article
Ahmad, D. A. J., Negm, O. H., Layth Alabdullah, M., Mirza, S., Hamed, M. R., Band, V., …Rakha, E. (2016). Clinicopathological and prognostic significance of mitogen-activated protein kinases (MAPK) in breast cancers. Breast Cancer Research and Treatment, 159(3), 457-467. https://doi.org/10.1007/s10549-016-3967-9

Background Mitogen-activated protein kinases (MAPKs) are signalling transduction molecules that have different functions and diverse behaviour in cancer. In breast cancer, MAPK is related to oestrogen receptor (ER) and HER2. Methods Protein express... Read More about Clinicopathological and prognostic significance of mitogen-activated protein kinases (MAPK) in breast cancers.

Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein (2016)
Journal Article
Alshareeda, A., Negm, O. H., Aleskandarany, M. A., Green, A. R., Nolan, C., Tighe, P. J., …Rakha, E. (2016). Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein. Breast Cancer Research and Treatment, 159(1), 41-53. https://doi.org/10.1007/s10549-016-3915-8

Impaired DNA damage response (DDR) may play a fundamental role in the pathogenesis of breast cancer (BC). RAD51 is a key player in DNA double-strand break repair. In this study, we aimed to assess the biological and clinical significance of RAD51 exp... Read More about Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein.

Impact of intratumoural heterogeneity on the assessment of Ki67 expression in breast cancer (2016)
Journal Article
Aleskandarany, M. A., Green, A. R., Ashankyty, I., Elmouna, A., Diez-Rodriguez, M., Nolan, C. C., …Rakha, E. (in press). Impact of intratumoural heterogeneity on the assessment of Ki67 expression in breast cancer. Breast Cancer Research and Treatment, 158(2), https://doi.org/10.1007/s10549-016-3893-x

In breast cancer (BC), the prognostic value of Ki67 expression is well-documented. Intratumoural heterogeneity (ITH) of Ki67 expression is amongst the several technical issues behind the lag of its inclusion into BC prognostic work-up. The immunohist... Read More about Impact of intratumoural heterogeneity on the assessment of Ki67 expression in breast cancer.

Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer (2016)
Journal Article
Green, A. R., Soria, D., Powe, D. G., Nolan, C. C., Aleskandarany, M. A., Szász, M., …Ellis, I. O. (2016). Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer. Breast Cancer Research and Treatment, 157(1), 65-75. https://doi.org/10.1007/s10549-016-3804-1

The Nottingham prognostic index plus (NPI+) is based on the assessment of biological class combined with established clinicopathologic prognostic variables providing improved patient outcome stratification for breast cancer superior to the traditiona... Read More about Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer.

RECQL4 helicase has oncogenic potential in sporadic breast cancers (2016)
Journal Article
Arora, A., Agarwal, D., Abdel-Fatah, T. M., Lu, H., Croteau, D. L., Moseley, P., …Madhusudan, S. (2016). RECQL4 helicase has oncogenic potential in sporadic breast cancers. Journal of Pathology, 238(4), 495-501. https://doi.org/10.1002/path.4681

RECQL4 helicase is a molecular motor that unwinds DNA, a process essential during DNA replication and DNA repair. Germ-line mutations in RECQL4 cause type II Rothmund–Thomson syndrome (RTS), characterized by a premature ageing phenotype and cancer pr... Read More about RECQL4 helicase has oncogenic potential in sporadic breast cancers.